Bernd Seizinger
Director/Board Member chez APTOSE BIOSCIENCES INC.
Fortune : 2 M $ au 31/03/2024
Profil
Bernd Robert Seizinger is the founder of CryptoMedix, Inc. (founded in 2015), where he currently holds the title of Executive Chairman & Chief Executive Officer.
He is also currently serving as an Independent Director at Aptose Biosciences, Inc. (since 2022), Oncolytics Biotech, Inc. (since 2015), Oxford BioTherapeutics Ltd.
(since 2016), BioInvent International AB (since 2018), Aprea Therapeutics AB (since 2015), Nykode Therapeutics ASA, TriMod Therapeutics Ltd.
(since 2011), Aprea Therapeutics, Inc. (since 2015), and Turbine Simulated Cell Technologies Ltd.
(since 2023).
Dr. Seizinger has held former positions as President & Chief Executive Officer at GPC Biotech AG (1998-2009), Independent Director at BioXell SpA (2010-2012), Director-Molecular Neuro-Oncology Laboratory at The General Hospital Corp.
(1992), Director at Santhera Pharmaceuticals Holding AG (2004-2011), Non-Executive Director at Bionor Pharma ASA, Chief Scientific Officer & Executive VP at Oscient Pharmaceuticals Corp., Principal at Princeton University, VP-Oncology Drug Discovery & Academic Alliances at Bristol-Myers Squibb Pharmaceutical Research Institute (1992-1996), and Associate Professor-Neuroscience at Harvard Medical School (1992).
He has also served as a Member-Supervisory Board at Agennix AG.
Dr. Seizinger's education includes a doctorate from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NYKODE THERAPEUTICS ASA
0,20% | 26/03/2024 | 650 000 ( 0,20% ) | 903 078 $ | 31/03/2024 |
ONCOLYTICS BIOTECH INC.
0,50% | 07/03/2024 | 380 126 ( 0,50% ) | 402 934 $ | 31/03/2024 |
APREA THERAPEUTICS, INC.
0,62% | 13/03/2024 | 33 685 ( 0,62% ) | 225 353 $ | 31/03/2024 |
| 30/08/2023 | 66 000 ( 0,10% ) | 104 932 $ | 31/03/2024 | |
APTOSE BIOSCIENCES INC.
0,11% | 05/02/2024 | 17 000 ( 0,11% ) | 28 220 $ | 31/03/2024 |
Postes actifs de Bernd Seizinger
| Sociétés | Poste | Début |
|---|---|---|
| NYKODE THERAPEUTICS | Director/Board Member | - |
| ONCOLYTICS BIOTECH INC. | Director/Board Member | 08/06/2015 |
| BIOINVENT INTERNATIONAL AB | Director/Board Member | 01/01/2018 |
| APREA THERAPEUTICS, INC. | Director/Board Member | 01/01/2015 |
| APTOSE BIOSCIENCES INC. | Director/Board Member | 13/09/2022 |
CryptoMedix, Inc.
 CryptoMedix, Inc. BiotechnologyHealth Technology CryptoMedix, Inc. operates as a biotechnology company, The company was founded in 2013 and is headquartered in Harpswell, ME. | Chief Executive Officer | - |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Director/Board Member | 14/12/2016 |
| Karolinska Institutet | Director/Board Member | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Director/Board Member | 01/01/2015 |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Bernd Seizinger
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Bernd Seizinger
| Max-Planck-Institute for Molecular Genetics | Doctorate Degree |
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| ONCOLYTICS BIOTECH INC. | Health Technology |
| BIOINVENT INTERNATIONAL AB | Health Technology |
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| NYKODE THERAPEUTICS | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | Health Technology |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
GPC Biotech AG
 GPC Biotech AG Miscellaneous Commercial ServicesCommercial Services GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey | Commercial Services |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
| Bristol-Myers Squibb Pharmaceutical Research Institute | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Agennix AG
 Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany. | Health Technology |
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Health Technology |
TriMod Therapeutics Ltd.
 TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | Health Technology |
CryptoMedix, Inc.
CryptoMedix, Inc. BiotechnologyHealth Technology CryptoMedix, Inc. operates as a biotechnology company, The company was founded in 2013 and is headquartered in Harpswell, ME. | Health Technology |
Turbine Simulated Cell Technologies Ltd.
 Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | Technology Services |
